OPRX Quote, Financials, Valuation and Earnings

AMN Healthcare Services, Inc. has a net margin of 2.99% compared to OptimizeRx Corp.'s net margin of -1.03%. OptimizeRx Corp.'s return on equity of 0.03% beat AMN Healthcare Services, Inc.'s return on equity of -14.43%.

OptimizeRx Corp. has a consensus price target of $24.33, signalling upside risk potential of 229.27%. On the other hand AMN Healthcare Services, Inc. has an analysts' consensus of $22.21 which suggests that it could grow by 8.89%. Given that OptimizeRx Corp. has higher upside potential than AMN Healthcare Services, Inc., analysts believe OptimizeRx Corp. is more attractive than AMN Healthcare Services, Inc..

OptimizeRx Corp. has a beta of 1.204, which suggesting that the stock is 20.441% more volatile than S&P 500. In comparison AMN Healthcare Services, Inc. has a beta of 0.234, suggesting its less volatile than the S&P 500 by 76.564%.

OptimizeRx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AMN Healthcare Services, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx Corp. pays -- of its earnings as a dividend. AMN Healthcare Services, Inc. pays out -- of its earnings as a dividend.

OptimizeRx Corp. quarterly revenues are $26.1M, which are smaller than AMN Healthcare Services, Inc. quarterly revenues of $748.2M. OptimizeRx Corp.'s net income of $779K is higher than AMN Healthcare Services, Inc.'s net income of -$7.7M. Notably, OptimizeRx Corp.'s price-to-earnings ratio is -- while AMN Healthcare Services, Inc.'s PE ratio is 18.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx Corp. is 1.27x versus 0.29x for AMN Healthcare Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Chemed Corp. has a net margin of 2.99% compared to OptimizeRx Corp.'s net margin of 12.01%. OptimizeRx Corp.'s return on equity of 0.03% beat Chemed Corp.'s return on equity of 23.87%.

OptimizeRx Corp. has a consensus price target of $24.33, signalling upside risk potential of 229.27%. On the other hand Chemed Corp. has an analysts' consensus of $443.00 which suggests that it could grow by 5.13%. Given that OptimizeRx Corp. has higher upside potential than Chemed Corp., analysts believe OptimizeRx Corp. is more attractive than Chemed Corp..

OptimizeRx Corp. has a beta of 1.204, which suggesting that the stock is 20.441% more volatile than S&P 500. In comparison Chemed Corp. has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.494%.

OptimizeRx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chemed Corp. offers a yield of 0.55% to investors and pays a quarterly dividend of $0.60 per share. OptimizeRx Corp. pays -- of its earnings as a dividend. Chemed Corp. pays out 11.99% of its earnings as a dividend. Chemed Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OptimizeRx Corp. quarterly revenues are $26.1M, which are smaller than Chemed Corp. quarterly revenues of $639.3M. OptimizeRx Corp.'s net income of $779K is lower than Chemed Corp.'s net income of $76.8M. Notably, OptimizeRx Corp.'s price-to-earnings ratio is -- while Chemed Corp.'s PE ratio is 22.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx Corp. is 1.27x versus 2.41x for Chemed Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Humana, Inc. has a net margin of 2.99% compared to OptimizeRx Corp.'s net margin of -2.39%. OptimizeRx Corp.'s return on equity of 0.03% beat Humana, Inc.'s return on equity of 6.77%.

OptimizeRx Corp. has a consensus price target of $24.33, signalling upside risk potential of 229.27%. On the other hand Humana, Inc. has an analysts' consensus of $223.88 which suggests that it could grow by 19.54%. Given that OptimizeRx Corp. has higher upside potential than Humana, Inc., analysts believe OptimizeRx Corp. is more attractive than Humana, Inc..

OptimizeRx Corp. has a beta of 1.204, which suggesting that the stock is 20.441% more volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.440, suggesting its less volatile than the S&P 500 by 55.989%.

OptimizeRx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Humana, Inc. offers a yield of 1.89% to investors and pays a quarterly dividend of $0.89 per share. OptimizeRx Corp. pays -- of its earnings as a dividend. Humana, Inc. pays out 36% of its earnings as a dividend. Humana, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OptimizeRx Corp. quarterly revenues are $26.1M, which are smaller than Humana, Inc. quarterly revenues of $32.5B. OptimizeRx Corp.'s net income of $779K is higher than Humana, Inc.'s net income of -$776M. Notably, OptimizeRx Corp.'s price-to-earnings ratio is -- while Humana, Inc.'s PE ratio is 19.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx Corp. is 1.27x versus 0.17x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regional Health Properties, Inc. has a net margin of 2.99% compared to OptimizeRx Corp.'s net margin of 22.34%. OptimizeRx Corp.'s return on equity of 0.03% beat Regional Health Properties, Inc.'s return on equity of --.

OptimizeRx Corp. has a consensus price target of $24.33, signalling upside risk potential of 229.27%. On the other hand Regional Health Properties, Inc. has an analysts' consensus of -- which suggests that it could grow by 400%. Given that Regional Health Properties, Inc. has higher upside potential than OptimizeRx Corp., analysts believe Regional Health Properties, Inc. is more attractive than OptimizeRx Corp..

OptimizeRx Corp. has a beta of 1.204, which suggesting that the stock is 20.441% more volatile than S&P 500. In comparison Regional Health Properties, Inc. has a beta of 1.054, suggesting its more volatile than the S&P 500 by 5.399%.

OptimizeRx Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regional Health Properties, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OptimizeRx Corp. pays -- of its earnings as a dividend. Regional Health Properties, Inc. pays out -- of its earnings as a dividend.

OptimizeRx Corp. quarterly revenues are $26.1M, which are larger than Regional Health Properties, Inc. quarterly revenues of $15.1M. OptimizeRx Corp.'s net income of $779K is lower than Regional Health Properties, Inc.'s net income of $3.4M. Notably, OptimizeRx Corp.'s price-to-earnings ratio is -- while Regional Health Properties, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OptimizeRx Corp. is 1.27x versus 0.08x for Regional Health Properties, Inc.. Usually stocks with elevated PS ratios are considered overvalued.